

- Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., & Viberti, G. (2006). Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. *New England Journal of Medicine*, 355(23), 2427-2443.
- Kannel, W. B. (1996). Blood pressure as a cardiovascular risk factor: prevention and treatment. *Jama*, 275(20), 1571-1576.
- Kasuga, M. (2006). Insulin resistance and pancreatic β cell failure. *Journal of Clinical Investigation*, 116(7), 1756-1760.
- Kelly, J. G., & O'Malley, K. (1992). Clinical pharmacokinetics of calcium antagonists. *Clinical pharmacokinetics*, 22(6), 416-433.
- Klag, M. J., Whelton, P. K., Randall, B. L., Neaton, J. D., Brancati, F. L., Ford, C. E., & Stamler, J. (1996). Blood pressure and end-stage renal disease in men. *New England Journal of Medicine*, 334(1), 13-18.
- Kreutz, R. (2011). Olmesartan/amlodipine: a review of its use in the management of hypertension. *Vascular health and risk management*, 7, 183.
- LaRosa, J. C., He, J., & Vupputuri, S. (1999). Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. *Jama*, 282(24), 2340-2346.